A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan

被引：0
作者：
Claire F. Verschraegen
Andrzej P. Kudelka
Wei Hu
Monique Vincent
John J. Kavanagh
Evelyne Loyer
Luc Bastien
A. Duggal
R. De Jager
机构：
[1] The University of Texas M. D. Anderson Cancer Center,Section of Gynecologic Medical Oncology
[2] The University of Texas M. D. Anderson Cancer Center,Department of Radiology
[3] MDS Pharma Services,undefined
[4] Daiichi Pharmaceutical Corporation,undefined
[5] University of New Mexico Cancer Research and Treatment Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2004年 / 53卷
关键词：
Camptothecin; Ovarian neoplasm; Topotecan resistance; Pharmacokinetics; Exatecan mesylate; DX-8951f;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 7
页数：6
相关论文
共 27 条
  • [1] Holschneider undefined(2000)undefined Semin Surg Oncol 19 3-undefined
  • [2] Berek undefined(1999)undefined Ann Oncol 10 87-undefined
  • [3] Marsden undefined(2000)undefined Semin Surg Oncol 19 11-undefined
  • [4] Gordon undefined(1997)undefined Proc Am Soc Clin Oncol 16 A1319-undefined
  • [5] Wall undefined(1996)undefined Ann N Y Acad Sci 803 1-undefined
  • [6] Mitsui undefined(1995)undefined Jpn J Cancer Res 86 776-undefined
  • [7] Lawrence undefined(1999)undefined Anticancer Drugs 10 655-undefined
  • [8] Green undefined(1992)undefined Invest New Drugs 10 239-undefined
  • [9] Oguma undefined(2000)undefined J Chromatogr B Biomed Sci Appl 740 237-undefined
  • [10] Yamaoka undefined(1978)undefined J Pharmacokinet Biopharm 6 165-undefined
123